Relmada Therapeutics (RLMD) Capital Expenditures (2014 - 2019)
Relmada Therapeutics (RLMD) posted quarterly Capital Expenditures of $84.8 million for Q4 2019, up 865708.14% quarter-over-quarter from $9800.0 in Q2 2018.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Capital Expenditures (2014 - 2019) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Capital Expenditures for 6 consecutive years, with $84.8 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Capital Expenditures changed N/A year-over-year to $84.8 million; the TTM figure through Dec 2019 stood at $84.9 million (changed N/A YoY), while the FY2020 annual figure was $182.1 million, up 114.56% from the prior year.
- Capital Expenditures grew to $84.8 million in Q4 2019 per RLMD's latest filing, from $9800.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $84.8 million in Q4 2019 and bottomed at $1310.0 in Q3 2015.
- Historically, Capital Expenditures has averaged $6.6 million across 5 years, with a median of $9800.0 in 2018.
- Annual changes were most pronounced in 2015 — Capital Expenditures jumped 7204.54% — and 2016, when it slumped 99.49%.
- Relmada Therapeutics' Capital Expenditures stood at $474795.0 in 2015, then plunged by 99.49% to $2434.0 in 2016, then increased by 6.45% to $2591.0 in 2017, then jumped by 278.23% to $9800.0 in 2018, then soared by 865708.14% to $84.8 million in 2019.
- Business Quant data shows RLMD's Capital Expenditures at $84.8 million in Q4 2019, $9800.0 in Q2 2018, and $2591.0 in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 84.85 Mn |
| Jun 30, 2018 | 9,800.00 |
| Sep 30, 2017 | 2,591.00 |
| Jun 30, 2017 | 2,202.00 |
| Mar 31, 2017 | 20,227.00 |
| Dec 31, 2016 | 2,434.00 |
| Sep 30, 2016 | 24,827.00 |
| Jun 30, 2016 | 23,043.00 |
| Mar 31, 2016 | 63,108.00 |
| Dec 31, 2015 | 474,795.00 |
| Sep 30, 2015 | 1,310.00 |
| Jun 30, 2015 | 3,870.00 |
| Mar 31, 2015 | 2,286.00 |
| Dec 31, 2014 | 6,500.00 |
| Sep 30, 2014 | 10,670.00 |
| Jun 30, 2014 | 3,673.00 |
| Mar 31, 2014 | 9,470.00 |